Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy

To this day, the phase III trial continues to be, as it was more than 60 years ago, the standard for the incorporation of new treatments in oncology. We currently have new tools such as NGS, Liquid Biopsy (LB), Big Data (BD) and Artificial Intelligence (AI) that will allow us to move towards faster and more universal research. This article analyzes the important weaknesses of phase III trials, the importance and current status of targeted therapy, and the contributions to LB decision-making and the knowledge of what happens in real life (RWD) that we facilitates BD and AI. Finally, what could be a clinical trial model that would take advantage of all these tools is proposed.